Biotech Values

[jq1234]

No, read the transcript, it is co-development agreement. ARRY has to pay portion of cost. ARRY's cost is capped both annually and in total but exact amount is not disclosed. ARRY paid NVS $9.2m for co-development cost incurred by NVS on MEK162 in 2012.

I honestly don't understand its decision process. As if it doesn't have enough on its plate already with 520 and 614 which are supposed to be in pivotal trials soon, it has to run a ph3 trial based on data not from MEK162, rather from Selumetinib, without selection of RAS/RAF marker.